MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1

Inhibitors of MET have not produced satisfactory outcomes in trials of patients with liver cancer. We investigated the mechanisms of liver tumor resistance to MET inhibitors in mice.